Levo-Del

Quick links to important sections

Levo-Del

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levo-Del

Quick Facts

Property Description
Active Ingredient Levocetirizine dihydrochloride
Form Tablets, Oral Solution, or Syrup
Pharmacological Class Selective H1-receptor antagonist
General Purpose Provides systemic relief from the effects of histamine and allergic symptoms
Origin Synthetic, derived from Cetirizine

What Type of Medicine is Levo-Del?

Levo-Del is a pharmaceutical preparation containing the active component Levocetirizine dihydrochloride. It is classified as a second-generation antihistamine, placing it within the pharmacological class of selective H1-receptor antagonists. This medicine is a synthetic compound derived as the purified R-enantiomer of the older, racemic drug Cetirizine. This structural refinement aims to concentrate the therapeutic action. Levocetirizine exhibits high specificity for peripheral H1 receptors, which suggests this medicine is effective at blocking the relevant receptors that cause discomfort.

Composition and General Purpose of Levo-Del

The composition of Levo-Del is based entirely on its single active agent, Levocetirizine dihydrochloride, making it a single-ingredient product. The medication is intended for systemic use, administered orally to allow it to be absorbed into the bloodstream, typically being supplied as Tablets, Oral Solution, or Syrup. The general purpose of Levo-Del is to provide systemic anti-allergic relief by functioning as an H1-blocker, preventing the inflammatory compound histamine from binding to its specific receptors. Second-generation antihistamines are effective in providing relief from histamine-mediated symptoms, which means this medicine helps lessen the overall burden of allergic symptoms.

Regulatory References

  1. Levocetirizine: MedlinePlus Drug Information

What side effects are possible with Levo-Del?

Possible side effects and safety information

The safety profile of Levo-Del (levocetirizine dihydrochloride) is structured by governmental regulatory agencies based on observed frequency and affected body systems. The officially documented adverse reactions are categorized primarily as common, uncommon, or rare.

Common adverse reactions, observed in clinical studies, frequently involve the Nervous System and Gastrointestinal System. These typically include somnolence or drowsiness, headache, fatigue, and dry mouth.

Uncommon reactions include generalized conditions such as asthenia (weakness) and abdominal pain.

Classification Examples of Officially Documented Adverse Reactions
Common Somnolence/Drowsiness, Headache, Fatigue, Dry Mouth
Uncommon Asthenia, Abdominal Pain

Serious Adverse Reactions

The official label notes rare but clinically significant adverse events based on post-marketing surveillance, including severe hypersensitivity reactions (e.g., anaphylaxis), seizures or convulsions, and hepatic impairment.

Population-Specific Safety Constraints

The medicine is contraindicated in patients with End-Stage Renal Disease (severe renal failure, defined as creatinine clearance less than 10 mL/min). Caution is advised for older adults due to the higher probability of reduced kidney function, which influences how the medicine is cleared from the body.

Safety Restrictions and Concurrent Use

Levo-Del is contraindicated in individuals with known hypersensitivity to the active ingredient or related compounds. Regulatory documents also advise against concurrent use with alcohol or other Central Nervous System (CNS) depressants, as this may lead to an additive reduction in alertness.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Levo-Del (Levocetirizine) is structured around documented Central Nervous System (CNS) manifestations and required emergency actions, which are dependent on age.

Documented Overdose Presentations

Overdose presentations primarily involve exaggerated CNS effects. In adults, the most common documented manifestation is drowsiness or excessive somnolence. The overdose presentation in children is distinct, typically beginning with signs of agitation and restlessness, which is then followed by a state of drowsiness. Symptoms observed following high-level intake, such as five times the recommended daily dose, may also include confusion, dizziness, fast heart rate (tachycardia), and inability to pass urine (urinary retention).

Immediate Actions and Management

Immediate action is mandatory in the event of a suspected overdose. The official instruction requires contacting a medical professional or a Poison Control Center immediately. Urgent medical services must be sought if the affected individual collapses, has a seizure, or experiences difficulty breathing.

Management is limited as there is no known specific antidote available for Levo-Del. The recommended clinical management consists of symptomatic or supportive treatment. Regulatory documentation explicitly states that Levocetirizine is not effectively removed from the body by dialysis, limiting this procedural option unless a co-ingested dialyzable substance is also involved.

Therapeutic Uses of Levo-Del

The medication is used in therapeutic domains focused on allergic conditions and is relevant when supportive symptom management is appropriate.

Supportive Management for Nasal and Ocular Discomfort

Levo-Del is commonly used across conditions presenting with acute episodes, relevant in conditions characterized by periods of heightened symptoms, such as seasonal allergic rhinitis and perennial allergic rhinitis. It helps address symptom clusters that may become intense or disruptive, such as those related to physical discomfort including sneezing, a runny nose, or irritated, watery eyes. This supportive relief generally contributes to improved comfort during periods of heightened symptoms, which may help patients cope more steadily with difficult episodes.

Easing Discomfort in Allergic Skin Conditions

Levo-Del is also applicable across domains where additional symptomatic support is needed for allergic skin issues like chronic hives (urticaria). It is relevant for managing symptoms that create noticeable functional strain, such as itching. This medication provides support that helps ease the overall symptom burden, and assists with maintaining functional stability when symptoms are more noticeable.


Quick Fact: Supportive Management for Symptoms that Interfere with Daily Functioning

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Levo-Del — Official Regulatory Information

The use of Levo-Del is officially defined by regulatory guidelines based on age, organ function, and specific health status. The eligibility profile establishes which populations may use the medicine and which are officially prohibited.

Eligibility Status Population or Condition
Contraindicated Patients with a known hypersensitivity to levocetirizine, cetirizine, or any component of the formulation.
Patients with end-stage renal disease (Creatinine Clearance <10 mL/min) or those undergoing hemodialysis.
Infants younger than 6 months of age.
Permitted Age Groups Adults and adolescents 12 years and older; Children 6 months to 11 years (solution formulation for younger children).
Restricted Use Older adults require renal function assessment due to potential decline in kidney clearance.
Patients with a history of epilepsy or convulsions or conditions predisposing to urinary retention.
Reproductive Status Use during pregnancy is conditional; use during lactation is generally not recommended as the drug is excreted in human milk.

Official regulatory documents strictly prohibit the medicine for populations with known non-eligibility and mandate special consideration for patients with moderate to severe renal impairment and specific comorbidities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Levo-Del (Levocetirizine dihydrochloride) details interaction patterns that primarily involve pharmacodynamic reinforcement and alterations in clearance.


Pharmacodynamic Interactions

Co-administration with alcohol (ethanol) or other Central Nervous System (CNS) depressants is advised to be avoided. This is due to the documented risk of additive effects, which may lead to additional reductions in alertness and increased impairment of CNS performance. This is a classification of Use with Precaution/Avoidance in official documents.


Pharmacokinetic Interactions

The drug is documented as unlikely to produce pharmacokinetic interactions by inhibiting or inducing common liver drug-metabolizing enzymes. However, studies with the racemate Cetirizine showed that Ritonavir increased the racemate’s plasma exposure ( AUC) by approximately 42% by affecting clearance. Co-administration with Theophylline also resulted in a small decrease in the clearance of the racemate.


Food and Population-Specific Notes

The presence of food does not affect the overall amount of the drug absorbed ( AUC); however, regulatory documents confirm that it delays the time to peak concentration ( T max) and lowers the peak concentration ( C max). For populations with renal impairment, the risk of adverse reactions is considered greater, necessitating awareness of any potential interaction consequences due to the drug’s primary reliance on renal excretion.

Mechanism of Action

How Levo-Del Works: Mechanism of Action

Levo-Del functions as a targeted modulator that initiates its pharmacodynamic action by binding to specific membrane-bound receptor or enzyme systems. This high-affinity molecular engagement serves to either block the effects of natural signaling molecules (antagonism) or allosterically modify the activity of the enzyme, thereby defining the primary mechanistic domain of the drug.

The action at the molecular target translates into an influence over defined neurohumoral pathways. Levo-Del acts to alter the signaling dynamics within these specific circuits, resulting in a reduction in the magnitude of signaling within these activated pathways. This pathway modulation is relevant to the subsequent influence on systemic activity.

By interfering with signal transduction and subsequent molecular cascades inside the cell, Levo-Del's action restricts the downstream physiological effects of heightened pathway activation. This process ultimately modifies the status of overactive physiological responses, leading to an altered operational status within the targeted biological systems that contributes to the resultant pharmacological profile.

Dosage and Administration Information

How to Use Levo-Del

Levo-Del is a medication intended for systemic use administered exclusively via the oral route. The medicine is available as a 5 mg scored tablet and an oral solution (2.5 mg per 5 mL). The administration schedule is standardized to once daily (qd), and it is recommended that the dose be taken specifically in the evening. The medicine can be taken with or without food, as its intake is independent of mealtimes. For accurate administration of the liquid form, a dedicated oral dosing device must be used, and the 5 mg tablet is scored to allow for the 2.5 mg dose, if required.


Standard Labeled Dosing Regimens

The dose taken must not exceed the specified daily maximum.

Population Recommended Daily Dose Max Daily Dose
Adults and Adolescents (ge 12 yrs) 5 mg (or 2.5 mg alternative) 5 mg
Children (6 to 11 yrs) 2.5 mg 2.5 mg
Children (6 months to 5 yrs) 1.25 mg (via oral solution) 1.25 mg

Use Constraints

A critical constraint on usage is that dosing requires modification for adults and adolescents with impaired kidney function, guided by estimated creatinine clearance. For example, severe impairment requires a dose of 2.5 mg only twice weekly. Conversely, no adjustment is required for solely hepatic impairment. If a dose is missed, the standard approach is to take the next scheduled dose at the usual time; doubling the dose is not recommended to compensate. The duration of use is typically for the period of required symptomatic management.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Levo-Del

Research into Levo-Del (levocetirizine dihydrochloride) has focused primarily on its study in conditions characterized by fluctuating or episodic manifestations. This overview summarizes the types of studies conducted, what outcomes research examined, and where gaps and limitations exist.


Evidence Base for Allergic Conditions

Research for Seasonal Allergic Rhinitis (SAR) primarily involves short-term, randomized controlled trials (RCTs) against a non-treatment (placebo). These studies examined symptom intensity (sneezing, nasal discharge, itching) and monitored patient-reported outcomes for Quality of Life (QoL) in adults and children six years and older.

For Perennial Allergic Rhinitis (PAR), studies explored symptoms that may vary in intensity over longer time intervals. Research includes both intermediate-duration RCTs (lasting four to six weeks) and some extension studies that monitored outcomes up to six months. Outcomes examined changes in persistent nasal symptoms and daily functional capacity.

Research into Chronic Urticaria (Hives) was evaluated in short-term RCTs, typically four to six weeks. The outcomes related to physical discomfort that research examined included the intensity of pruritus (itching) and the reduction in the size and number of wheals in adults and children. Findings describe patterns observed in these trials, and regulatory reviews classify the evidence for all three indications as High quality.


Study Duration and Research Gaps

Long-term effects are not fully established across all indications, as the majority of core evidence is concentrated on short-term responses (two to six weeks). While Levo-Del was evaluated in children aged six and older, data for older adults and very young pediatric populations remain insufficient.

Scientific reviews note that comparative evidence is lacking for direct comparisons against all available second-generation treatments. Furthermore, evidence quality varies across studies, and reports indicate that inconsistency was reported across some studies for certain symptom measurements. This highlights that a complete understanding of long-term outcomes is an area where research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Levo-Del (FAQ)


Q: What is the main difference between Levo-Del and [Commonly Known Competitor Drug]?

Official regulatory documents classify the active ingredient in Levo-Del (levocetirizine) as a selective H1-receptor antagonist. This means it targets a specific type of receptor involved in allergic reactions. Furthermore, the medicine is described as the R-enantiomer of cetirizine, a specific structural feature noted in the drug’s pharmacological description.

Q: Can Levo-Del be taken with common over-the-counter pain relievers?

Studies indicate that the active ingredient in Levo-Del is not documented to inhibit the common liver enzymes (CYP isoenzymes) that metabolize many other medicines, suggesting a low potential for metabolic drug interaction. Nevertheless, official information advises patients to inform their healthcare provider about all medicines, including over-the-counter pain relievers, for guidance regarding potential co-administration.

Q: Are there any specific foods or drinks that should be avoided while taking Levo-Del?

Regulatory documents explicitly advise against the consumption of alcohol while using Levo-Del due to the potential for increased drowsiness and central nervous system (CNS) impairment, which can affect alertness. Aside from alcohol, the official product information states that the drug can be taken with or without food.

Q: Does Levo-Del interact with blood pressure medications?

While regulatory documents list specific interaction warnings for CNS depressants, Ritonavir, and Theophylline, they do not generally list blood pressure medications as contraindicated. The medicine's low potential for altering the metabolism of other drugs suggests a low risk of metabolic interaction with many blood pressure medicines, but a healthcare provider should always be informed of co-administered drugs.

Q: Can I take Levo-Del if I am taking a supplement like [Common Supplement]?

Health authority information strongly advises patients to tell their doctor or pharmacist about all prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products they are taking. Providing this comprehensive information helps the healthcare provider assess any potential risk of interaction.

Q: What should a person do if they stop taking Levo-Del suddenly?

Official drug safety communication notes that in rare instances, severe generalized itching has been reported in patients who stop taking levocetirizine after daily, long-term use. If a person experiences severe itching or other new symptoms after discontinuing the medication, they should contact a healthcare provider for guidance.

Q: Is Levo-Del used for anything besides its main approved purpose?

The official regulatory label specifies that the medicine is indicated for the relief of symptoms related to seasonal and perennial allergic rhinitis, and the treatment of chronic idiopathic urticaria (hives). Any use outside of these specific, approved conditions is not covered by the official indication.

Q: Is Levo-Del known to cause weight gain or weight loss?

Weight changes are sometimes reported in post-marketing surveillance for the active ingredient in Levo-Del. Specifically, weight gain has been reported as an adverse reaction in clinical reviews, though it is considered a less common effect than the most frequently cited side effects.

Q: How long does the effect of a single dose of Levo-Del usually last?

The time it takes for the concentration of the medicine in the body to be reduced by half (the mean plasma elimination half-life) is approximately 8 to 9 hours in healthy adults. This half-life measurement provides the pharmacological basis for the standard once-daily dosing schedule.

Q: Why do doctors prescribe Levo-Del instead of other options?

The active ingredient is classified as a second-generation antihistamine, which selectively targets specific receptors (H1-receptors). This classification is a factor in decision-making, and is a classification often associated with specific characteristics when compared to older generation antihistamines.

Q: Does Levo-Del require special lab monitoring or blood tests?

Official documents do not mandate routine blood tests for all users of the medicine. However, special monitoring of kidney function (creatinine clearance) is required for patients who have impaired renal function, as the dose must be adjusted accordingly.

Q: What are the signs of a serious allergic reaction to Levo-Del?

Regulatory documents list severe hypersensitivity reactions (like anaphylaxis) as a rare but serious side effect. Signs can include hives, rash, difficulty breathing, or swelling of the face, lips, tongue, or throat. Immediate emergency medical attention is necessary if these signs occur.

Q: Does Levo-Del affect fertility or reproductive health?

Non-clinical data, which uses models other than humans, did not show effects on male or female fertility when the active ingredient was studied. However, official patient labels may not contain specific human data on fertility effects.

Q: Are generic versions of Levo-Del available?

Yes, the active ingredient in Levo-Del, Levocetirizine dihydrochloride, is widely available as a generic medicine. This generic version is offered in various forms, such as tablets and oral solutions, as listed in official drug databases.

Q: How should a person stop taking Levo-Del if directed by their doctor?

The official product information does not specify a tapering schedule for discontinuation. Instead, it is important for the patient to discuss the safest and most appropriate way to stop treatment with their doctor, especially if the medicine has been taken daily for a long time.

Q: What does the term 'indicated use' mean for Levo-Del?

The 'indicated use' refers to the specific conditions and symptoms for which a medicine has been officially reviewed, tested, and approved by governmental regulatory bodies. For Levo-Del, this includes relief from certain allergic rhinitis symptoms and chronic hives.

Q: What happens in the body if too much Levo-Del is taken?

The overdosage section in regulatory information notes that symptoms may vary by age. Adults may primarily experience drowsiness, while children may initially show agitation and restlessness before becoming drowsy. Contacting a Poison Control Center or seeking emergency medical help is advised immediately.

Q: Is the term 'Levo-Del' a brand name or a generic name?

The core medicine is Levocetirizine dihydrochloride, which is the generic name of the active compound. 'Levo-Del' is a proprietary name, which is often referred to as a brand name or trade name under which the medicine is marketed.

How should Levo-Del be stored and disposed of?

How to Store and Dispose of Levo-Del?

Official regulatory documents define specific requirements for storing and disposing of Levo-Del (Levocetirizine dihydrochloride) to ensure product integrity and safety.


Storage and Handling Requirements

Requirement Type Official Instructions
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep in the original container and protect from excessive heat and moisture. Do not freeze the oral solution or syrup.
Child Safety Keep out of the sight and reach of children.

Stability and Disposal

Liquid formulations have a defined limited stability period after first opening; remaining product must be discarded after this time. Disposal of unused or expired product must follow local regulations, utilizing medicine take-back programs when available. The product must not be thrown away via wastewater or routine household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Levo-Del found in:

A-Z Index: